Loading news...
Bamco Inc. NY acquired a new stake in Roivant Sciences Ltd. (NASDAQ: ROIV) during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 105,000 shares of the company's stock, valued at approximately $1,589,000. A number of other hedge funds and
Roivant Sciences Ltd. (ROIV) Presents at Leerink Global Healthcare Conference 2026 Transcript
Stock News Wall Street whipsawed by Mideast turmoil: The SPDR S&P 500 ETF Trust (SPY) fell Tuesday, then futures steadied as oil volatility and safeâhaven flo
Roivant Sciences Ltd. (ROIV) Discusses $2.25 Billion Global Settlement Resolving COVID Vaccine Patent Litigation Transcript
Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna's Section 1498 appeal If the $1.3 billion payment is realized, this settlement will be the largest disclosed patent settlement paid in the pharmaceutical industry and the second largest in any industry Settlement holds Moderna accountable for infringement and provides for the court to enter judgment of no invalidity on the four Genevant/Arbutus patents asserted in the case Genevant grants Moderna a global non-exclusive license to its LNP delivery technology for SM-102-containing mRNA vaccines for infectious disease and a covenant not to sue for certain Genevant/Arbutus patents and Moderna products, ending all patent-infringement litigation against Moderna arising from its unauthorized use of the technology in its COVID-19 vaccines Pfizer/BioNTech litigation is ongoing in the United States following a favorable Markman ruling issued in September 2025; Comirnaty sales represent ~2/3 of global COVID-mRNA vaccine sales to date Roivant's board of directors has approved a $1 billion share repurchase program, inclusive of the $500 million authorization that was approved in June 2025 Roivant will host an investor call to discuss these updates today, March 3, 2026, at 4:45 p.m. ET BASEL, Switzerland and LONDON and NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio and a subsidiary of Roivant, and Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on infectious disease, have entered into a $2.25 billion global settlement with Moderna, Inc. to resolve all U.S. and international enforcement actions involving Moderna's unauthorized use of Genevant's and Arbutus' LNP delivery technology in its COVID-19 vaccines, including Spikevax ®.
Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna's Section 1498 appeal If the $1.3 billion payment is realized, this settlement will be the largest disclosed patent settlement paid in the pharmaceutical industry and the second largest in any industry Settlement holds Moderna accountable for infringement and provides for the court to enter judgment of no invalidity on the four Genevant/Arbutus patents asserted in the case Genevant grants Moderna a global non-exclusive license to its LNP delivery technology for SM-102-containing mRNA vaccines for infectious disease and a covenant not to sue for certain Genevant/Arbutus patents and Moderna products, ending all patent-infringement litigation against Moderna arising from its unauthorized use of the technology in its COVID-19 vaccines Pfizer/BioNTech litigation is ongoing in the United States following a favorable Markman ruling issued in September 2025; Comirnaty sales represent ~2/3 of global COVID-mRNA vaccine sales to date Arbutus announces that it is currently evaluating a return of capital to shareholders for the third quarter of calendar year 2026, in conjunction with the upfront payment Roivant will host an investor call to discuss these updates today, March 3, 2026, at 4:45 p.m. ET BASEL, Switzerland and VANCOUVER, British Columbia, March 03, 2026 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio and a subsidiary of Roivant Sciences Ltd.
Roivant Sciences Ltd. (ROIV) Presents at TD Cowen 46th Annual Health Care Conference Transcript
FDA assigns PDUFA target action date in the third quarter of calendar year 2026 with launch expected at the end of September 2026 Priority Review supported by positive Phase 3 VALOR results, the first positive 52-week placebo-controlled trial in dermatomyositis If approved, brepocitinib would represent the first targeted therapy approved for dermatomyositis DURHAM, N.C., March 03, 2026 (GLOBE NEWSWIRE) -- Priovant Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for brepocitinib for the treatment of dermatomyositis (DM) and has granted the application Priority Review.
Guru Stock PicksDavid Herro has made the following transactions:Reduce in CNH by 1.5%Sold out in XAMS:EXOAdd in TSE:6273 by 1.02%New position in LSE:ULVROakmark
Stock News Nvidia's big test: Nvidia (NVDA) reports after the bell with options implying a 5.6% move â the smallest expected postâearnings swing in at least
Guru Stock PicksPaul Singer has made the following transactions:Reduce in LUV by 8.86%Stock News Meta taps AMD for AI buildout: Meta Platforms (META) signed a m
Stock News Dimon warns on credit cycle: JPMorgan Chase (JPM) CEO Jamie Dimon cautioned that elevated asset prices and growing banking competition echo preâ200
Roivant Sciences Ltd. (NASDAQ: ROIV - Get Free Report) CEO Eric Venker sold 200,000 shares of the firm's stock in a transaction on Friday, February 13th. The stock was sold at an average price of $26.49, for a total value of $5,298,000.00. Following the completion of the transaction, the chief executive officer directly owned 1,654,597 shares
Jefferies Group (Trades, Portfolio)'s Strategic Moves in Q4 2025: A Detailed Analysis Jefferies Group (Trades, Portfolio) recently submitted its 13F filing for
New York State Common Retirement Fund lifted its stake in shares of Roivant Sciences Ltd. (NASDAQ: ROIV) by 25.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 229,037 shares of the company's stock after acquiring an additional 46,344 shares during the
Roivant Sciences Ltd. (NASDAQ: ROIV - Get Free Report)'s stock price hit a new 52-week high on Friday. The stock traded as high as $25.49 and last traded at $24.7320, with a volume of 3598048 shares. The stock had previously closed at $21.14. Key Headlines Impacting Roivant Sciences Here are the key news stories impacting
Roivant: The Next Telavant Has Arrived With Brepocitinib's Blockbuster Data (Rating Upgrade)
Roivant Sciences Ltd. (ROIV) Q3 2025 Earnings Call Transcript
Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.27.
BASEL, Switzerland and LONDON and NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced positive Phase 2 results for brepocitinib in cutaneous sarcoidosis (CS) and reported its financial results for the third quarter ended December 31, 2025.